Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 166 results for atrial fibrillation

  1. There is a need for additional research on the management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents.

    preventing stroke and systemic embolism in people with non-valvular atrial fibrillation Number TA275 Date issued February 2013

    Research recommendation
    Published
    9 June 2015

  2. During this appraisal it was noted that there is a need for additional research on the management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents.

    preventing stroke and systemic embolism in people with non-valvular atrial fibrillation Number TA275 Date issued February 2013

    Research recommendation
    Published
    10 August 2021

  3. Board, executive team and senior leaders interests register

    (non-remunerated) Chair Pfizer/Bristol Myers Squibb independent atrial fibrillation detection improvement grants – not product related....

  4. Board, executive team and senior leaders interests register

    (non-remunerated) Chair Pfizer/Bristol Myers Squibb independent atrial fibrillation detection improvement grants – not product related....

  5. Board, executive team and senior leaders interests register

    (non-remunerated) Chair Pfizer/Bristol Myers Squibb independent atrial fibrillation detection improvement grants – not product related....

  6. The committee recommended that data should be collected to evaluate the system impact of adopting the lead‑I ECGs on both primary and secondary care. In particular, data should be collected on how ECGs generated by the devices would be interpreted in practice, including staff time needed to interpret the ECG traces and associated costs.

    Comes from guidance Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care...

    Research recommendation
    Published
    25 October 2019

  7. Enhancing the Quality of Heart Failure Care

    Job: AHSN Heart Failure & Atrial Fibrillation Programme Lead Organisation: Kent,

    Shared learning
    Last updated
    28 October 2019

  8. Ivabradine for treating chronic heart failure (TA267)

    Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.

    Technology appraisal guidance
    Published
    28 November 2012
    View recommendations

    Sections for TA267

  9. Research recommendations

    people with atrial fibrillation: - Which automated blood pressure monitors are suitable for people with hypertension and atrial...

  10. Personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome (IPG724)

    Evidence-based recommendations on personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome. This involves opening the chest through the breastbone and wrapping a mesh around the outside of the aorta at the part closest to the heart.

    Interventional procedures guidance
    Published
    18 May 2022
    View recommendations

    Sections for IPG724

  11. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)

    Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.

    Technology appraisal guidance
    Published
    15 December 2010
    View recommendations

    Sections for TA210

  12. Leadless cardiac pacemaker implantation for bradyarrhythmias (IPG626)

    Evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias in adults. This involves inserting a device into the heart that helps it beat at a normal rate.

    Interventional procedures guidance
    Published
    29 August 2018
    View recommendations

    Sections for IPG626

  13. Transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair (IPG707)

    Evidence-based recommendations on transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair in adults. This involves inserting a bioprosthetic mitral valve into an existing mitral valve ring to treat a leaking mitral valve, without needing repeat open heart surgery.

    Interventional procedures guidance
    Published
    22 September 2021
    View recommendations

    Sections for IPG707

  14. Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis (IPG706)

    Evidence-based recommendations on transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis in adults. This involves inserting a new valve inside a failed bioprosthetic valve to replace the faulty one without needing repeat open heart surgery.

    Interventional procedures guidance
    Published
    22 September 2021
    View recommendations

    Sections for IPG706

  15. Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

    Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    24 February 2021
    View recommendations

    Sections for TA679